Dutton Associates Indepedent Research:
We are initiating coverage of Sunwin International Neutraceuticals, Inc. with a Strong Speculative Buy rating. The Company is principally engaged in the development, production and marketing of nutraceutical products, with a prime focus on calorie-free natural sweeteners, traditional Chinese medicine (TCM)-based veterinary medications and animal additives, and TCM-formula extracts for both human and animals. Most of these products are sold on a wholesale basis in the domestic market via a nationwide distribution network, as well as by exporting to overseas markets.
--> Kursziel: 1,85 Dollar
Wall Street Research Report
COMPANY PROFILE
Sunwin International Neutraceuticals, Inc. (www.sunwin.biz), headquartered in Qufu, in the Shandong Province of the People?s Republic of China, is a diversified nutraceutical company engaged in the development, manufacturing and international sale of a variety of health products for humans and animals. The Company?s agricultural processing expertise and convenient access to raw materials in select Chinese farmlands result in high-quality and cost-effective natural products that straddle the healthcare industry and the food & beverage marketplace. Products offered by the Company include a powerful low-calorie natural sweetener called stevioside, numerous herbal extracts rooted in traditional Chinese medicine (TCM), as well as a variety of veterinary medicines and feed supplements. Their innovative nature has in recent years earned state-level recognition and several industry awards for the Company. For the fiscal year ended April 30, 2005, the Company?s revenues rose 11% to $12,114,006, and the net income increased 78% to $829,114, or $.02 per share. In the first nine months of fiscal 2006 ended January 31, 2006, total revenues climbed nearly 21% to $11,065,853, and net income grew 474% to $2,025,104, or $0.04. Last September, the Company completed an upgrade and expansion of most of its manufacturing facilities, which not only increased stevioside production capacity to 300 tons per year, or a double-digit percentage share of the global demand, but also fulfilled GMP requirements mandated since the beginning of 2006 by the central government on producers of Chinese herb and veterinary medicines. Trading on the OTC Bulletin Board under the symbol SUWN, the Company is well positioned to immediately capitalize on the temporary competitive advantage resulting from the GMP certification and benefit from the overall growing health concerns among consumers globally, increasing popularity of organic foods and medicines, and the strong condition of the Chinese economy.
--> In Summe als ein riesen Potential.
|
Thread abonnieren
ETF-Sparplan